Back to top

Image: Bigstock

ABIOMED Unveils Digital Platform CAMP PCI for CAD Treatment

Read MoreHide Full Article

ABIOMED Inc. (ABMD - Free Report) recently launched a revolutionary digital education platform called CAMP PCI, which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention. It is designed to enhance patient outcomes and quality of life with supported high-risk PCI by using the best practices, techniques and technologies to enable safer, more efficient and complete revascularization.

This is expected to boost the company’s Impella product line with respect to product innovation.

More About CAMP PCI

CAMP PCI utilizes contemporary and advanced digital content such as live virtual observerships and proctorships from leading interventional cardiologists as well as educational modules designed for all levels of clinical expertise. The broad-based and advanced curriculum comprises topics such as access and closure technology optimization, advanced imaging, therapeutic best practices for coronary artery disease (CAD), and the importance of Impella hemodynamic support in appropriately selected high-risk patients to attain safe as well as complete revascularization. CAMP PCI should enable physicians to learn how to better protect the myocardium and enhance overall outcomes in this complex patient population.

CAMP PCI was designed for the treatment of patients suffering from coronary artery disease and heart failure, and to cater to the need for continuous improvement in contemporary PCI techniques and tools. Markedly, the COVID-19 pandemic has increased the need for digital and on-demand medical training.

CAMP PCI can help to deliver better patient outcomes, reduced mortality rates, and enhanced longevity of patients.

The curriculum is developed to improve physician training on patient selection, best treatment practices, advanced tools and techniques, as well as program growth and sustainability.

Recent Developments

In June, the company announced that the FDA has approved investigational device exemption application to initiate an early feasibility study with a first-in-human trial of the company’s 9 French (Fr) Impella ECP heart pump. The Impella ECP, which stands for expandable cardiac power, will be assessed in high-risk percutaneous coronary intervention (PCI) patients.

Around the same time, the company’s Impella RP attained the FDA’s Emergency Use Authorization for treating COVID-19-related right heart failure or decompensation, including pulmonary embolism.

Market Prospects

Per a report by, the global coronary artery disease treatment devices market is likely to witness a CAGR of 5.5% over the 2018-2024 period.

Price Performance

In the past three months, the stock has gained 70% compared with 26.1% growth of the industry.

Zacks Rank and Key Picks

ABIOMED currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space include HMS Holdings (HMSY - Free Report) , Surmodics (SRDX - Free Report)  and LabCorp (LH - Free Report) .

HMS Holdings’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #1.

LabCorp’s long-term earnings growth rate is estimated at 6.1%. It currently carries a Zacks Rank #2.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>